Regulacje i polityka gospodarcza · 12/12/2001

Bristol Myers Squibb to License Celgene's Multiple Myeloma Treatment for $5.9 Billion

Bristol Myers Squibb has announced its intention to grant an exclusive patent license to Celgene's multiple myeloma treatment, Reclinaq, for $5.9 billion, marking a significant development in the pharmaceutical industry.